Insurers Push Accelerated Review Of 2nd, 3rd Drugs In Class To Cut Prices

June 25, 2015 at 5:02 PM
The acting head of the health insurance lobby and a former FDA official say the agency could spur competition to lower drug prices by also giving accelerated review to so called me-too products after a first-in-class drug receives breakthrough status, such as Gilead Sciences' hepatitis C cure Sovaldi, which has been at the center of the debate over high drug prices. Scott Gottlieb, former FDA deputy commissioner for medical and scientific affairs and a resident fellow at the American Enterprise...

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.